MedTrace Logo

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

NCT06807606 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-04-28

No results posted yet for this study

Summary

The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.

Conditions

Interventions

DRUG

Drugs Cyclophosphamide

Given as standard of care treatment through IV infusion

DRUG

Fludarabine

Given as standard of care treatment through IV infusion

DRUG

Thiotepa

Given as standard of care treatment through IV infusion

DRUG

Tacrolimus

Given as standard of care treatment through IV infusion

DRUG

Mycophenolate mofetil

Given as standard of care treatment through IV infusion

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Warren Fingrut, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2027-11-30
Completion
2029-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06807606 on ClinicalTrials.gov